WIRED tested samples of four popular peptide products marketed online and found they don't contain what manufacturers claim. The findings expose minimal oversight in an industry experiencing rapid growth.
Lab analysis revealed the peptide products sold through bodegas and online retailers either contained no peptides or failed to match their advertised formulations. The tests underscore how the supplement sector operates with minimal regulatory scrutiny.
Peptides—short chains of amino acids—have become a wellness trend, with products promising muscle growth, anti-aging effects, and improved performance. As demand surges, manufacturers and retailers have capitalized on limited FDA oversight of supplements.
Unlike pharmaceuticals, supplements require no pre-market approval. The FDA can only act after problems emerge. This framework allows companies to make claims with little verification, and consumers have no reliable way to confirm product authenticity.
The bodega peptide phenomenon reflects a broader pattern: viral health trends often outpace regulatory enforcement. Consumers purchasing these products have no assurance they contain active ingredients or safe compounds. The testing results suggest the peptide market needs stronger accountability mechanisms before popularity expands further.
China has enacted sweeping new restrictions on overseas travel for its citizens, including exit bans and fines, as President Xi Jinping tightens control over state secrets and advanced technology.
The US Census Bureau, which houses sensitive data on nearly every American and determines congressional representation and federal funding allocation, has hired numerous staffers from a MAGA-aligned think tank.
A bipartisan congressional effort aims to restrict automated license plate readers by threatening to withhold federal highway funding from non-compliant states. The approach mirrors the national drinking age enforcement model.
Major technology companies will continue aggressive fundraising and capital spending despite growing calls to slow artificial intelligence development, according to AllianceBernstein analysts.